Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study

Background: To date, only a few real-world-setting studies evaluated apremilast effectiveness in psoriatic arthritis (PsA). The aims of this retrospective observational study are to report long-term Disease Activity Index for Psoriatic Arthritis (DAPSA) response of apremilast in PsA patients and to analyze the predictors of clinical response. Methods: All PsA consecutive patients treated with apremilast in fifteen Italian rheumatological referral centers were enrolled. Anamnestic data, treatment history, and PsA disease activity (DAPSA) at baseline, 6 months, and 12 months were recorded. The Mann–Whitney test and chi-squared tests assessed the differences between independent groups, whereas the Wilcoxon matched pairs signed-rank test assessed the differences between dependent samples. Logistic regressions verified if there were factors associated with achievement of DAPSA low disease activity or remission at 6 and 12 months. Results: DAPSA low disease activity or remission rates at 6 and 12 months were observed, respectively, in 42.7% (n = 125) and 54.9% (n = 161) patients. Baseline DAPSA was inversely associated with the odds of achieving low disease activity or remission at 6 months (odds ratio (OR) 0.841, 95% confidence interval (CI) 0.804–0.879; p < 0.01) and at 12 months (OR 0.911, 95% CI 0.883–0.939; p < 0.01). Conclusions: Almost half of the PsA patients receiving apremilast achieved DAPSA low disease activity or remission at 6 and 12 months. The only factor associated with achievement of low disease activity or remission at both 6 and 12 months was baseline DAPSA.

[1]  V. Bruzzese,et al.  Apremilast retention rate in clinical practice: observations from an Italian multi-center study , 2022, Clinical Rheumatology.

[2]  D. Gladman,et al.  Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis , 2022, The Journal of Rheumatology.

[3]  K. de Vlam,et al.  Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study , 2022, Advances in Therapy.

[4]  A. Ogdie,et al.  Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results , 2020, The Journal of Rheumatology.

[5]  L. Coates,et al.  Treatment‐to‐Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations , 2020, Arthritis care & research.

[6]  R. Lucchetti,et al.  Musculoskeletal ultrasound in monitoring response to apremilast in psoriatic arthritis patients: results from a longitudinal study , 2019, Clinical Rheumatology.

[7]  C. Edwards,et al.  Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial , 2018, Rheumatology.

[8]  H. Marzo-Ortega,et al.  Apremilast for the treatment of active psoriatic arthritis: a single-centre real-life experience. , 2018, Rheumatology.

[9]  L. Coates,et al.  Psoriatic arthritis: state of the art review , 2017, Clinical medicine.

[10]  M. Cutolo,et al.  A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial , 2016, The Journal of Rheumatology.

[11]  C. Edwards,et al.  Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3) , 2016, Annals of the rheumatic diseases.

[12]  M Cutolo,et al.  European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update , 2015, Annals of the rheumatic diseases.

[13]  D. Gladman,et al.  Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor , 2014, Annals of the rheumatic diseases.

[14]  A. Kavanaugh,et al.  Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis , 2010, Annals of the rheumatic diseases.

[15]  Dafna Gladman,et al.  Classification criteria for psoriatic arthritis: development of new criteria from a large international study. , 2006, Arthritis and rheumatism.

[16]  F. Wolfe,et al.  Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues , 2004, Annals of the rheumatic diseases.

[17]  R. Caporali,et al.  Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients. , 2019, Clinical and experimental rheumatology.